Tissue Regenix (TRX) completed its acquisition of CellRight Technologies. The purchase price was previously noted as US $30.0MM.
The transaction more than doubles TRX’s U.S. sales and pairs complementary platforms of soft tissue regeneration with CellRight’s regenerative osteoconductive bone scaffolds.
TRX plans to launch its OrthoPure™ HT decellularized human tendon in the U.S. in early 2018, for an initial application in anterior cruciate ligament repair.
Jesus Hernandez, CellRight’s Chief Executive Officer, will join Tissue Regenix as Chief Scientific Officer.
Tissue Regenix (TRX) completed its acquisition of CellRight Technologies. The purchase price was previously noted as US $30.0MM.
The transaction more than doubles TRX's U.S. sales and pairs complementary platforms of soft tissue regeneration with CellRight's regenerative osteoconductive bone scaffolds.
TRX plans to launch its OrthoPure™...
Tissue Regenix (TRX) completed its acquisition of CellRight Technologies. The purchase price was previously noted as US $30.0MM.
The transaction more than doubles TRX’s U.S. sales and pairs complementary platforms of soft tissue regeneration with CellRight’s regenerative osteoconductive bone scaffolds.
TRX plans to launch its OrthoPure™ HT decellularized human tendon in the U.S. in early 2018, for an initial application in anterior cruciate ligament repair.
Jesus Hernandez, CellRight’s Chief Executive Officer, will join Tissue Regenix as Chief Scientific Officer.
Copy to clipboard 
